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Abstract
Background: Investigations focusing and implementing on the impact of cancer on health-related
quality of life (HRQoL) by the way of a mean comparison between cancer patients and subjects
from the general population, are scarce and usually cross-sectional. Longitudinal application of
HRQoL instruments to a general, initially healthy population allows for change to be assessed as an
event occurs, rather than afterwards. The objective of the present study was to investigate the
impact of new cancer on HRQoL.
Methods: The 36-item Short Form (SF-36) and 12-item General Health Questionnaire (GHQ-12)
were applied to the French SU.VI.MAX cohort in 1996 and 1998. A controlled longitudinal study
was used to determine the impact on HRQoL of newly diagnosed cancer: 84 patients with cancer
that occurred between the 2 HRQoL measures were compared with 420 age- and sex-matched
cancer-free controls.
Results: Initial HRQoL level was similar in the two groups. A new cancer had a particularly marked
effect on the SF-36 Physical functioning, Role-physical and General health dimensions (more than
6.6-point difference in change in HRQoL evolution on a 0–100 scale). The Bodily pain and Vitality
dimensions were less severely affected (difference in change varying from 4.4 to 6.3 points), and
there was no effect on either the GHQ-12 score or the SF-36 Mental health, Role-emotional and
Social functioning dimensions.
Conclusions: The negative impact of cancer on the lives of patients was assessed in terms of
HRQoL. The aspects most likely to be affected were those with a physical component, and general
health perceptions. These results can thus help quantify the impact of a new cancer on HRQoL
evolution and potentially facilitate early intervention by identifying the most affected HRQoL
domains.
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Background
Technological advances in cancer therapy led to improve
objective outcomes such as survival, objective response to
treatment, and toxicity. As cancer care management
increased its effectiveness, opportunities and need for
using patient's health-related quality of life (HRQoL)
became more apparent. In other words, physicians now
have an opportunity to add life to years, as well as adding
years to life.
Although no formal definition of HRQoL has yet been
generally accepted, there is broad agreement that it is a
subjective, multidimensional construct comprising three
major aspects of functioning: physical, psychological and
social. However, this is not a complete picture, as a broad
range of aspects may be included such as cognitive func-
tioning [1,2].
Despite the difficulties of going from concept to quantifi-
cation of patient perceptions, the number of instruments
available to measure HRQoL psychometrically has
increased rapidly. Assessments can now be made in a vari-
ety of distinctive ways using both specific and generic
measures. Generic scales include items that cover all
major aspects of a person's health and are applicable
whatever the person's conditions. Specific scales include
only those items likely to be affected by the disease con-
cerned or its treatment, and have been developed for par-
ticular disease categories, principally cancer (ranging from
cancer overall to specific treatments/phases). Most
HRQoL instruments were designed for self-administra-
tion and are relatively short. There is no gold-standard
questionnaire, and the choice is based on psychometric
properties, research objectives and study design [1,3-5].
HRQoL is increasingly used as an outcome measure in
oncology research studies [6,7], appearing in a variety of
forms in numerous different publications. For example,
HRQoL measures may provide descriptive information
about patients with cancer and allow to explore the rela-
tionships between HRQoL and socio-demographic factors
(i.e. sex, age, social situation, and education level) [8,9].
Other investigations focus on differences in HRQoL
between groups of cancer patients classified by various
characteristics such as disease stage [10-13], prognosis
[14] and treatment [15-23]. However, most studies look
at the influence of treatment on HRQoL, either to deter-
mine the impact of a particular intervention or to explore
which of several has a better effect. The efficacy of new
therapeutic interventions is now evaluated in terms of
their impact on both quantity and quality of life, with the
aim of extending survival and improving HRQoL. HRQoL
scores can also be used to predict survival, as the better
they are, the longer the patient is likely to live [24-28]. All
such studies to date have been conducted in populations
with established cancer diagnoses.
Investigations comparing HRQoL in cancer patients and
subjects from the general population are scarce. They are
usually cross-sectional, assessing HRQoL at different
times during the course of cancer, and the data collected
are generally limited to clinical information (cancer diag-
nosis, stage, treatment, and prognosis) and demographics
(age, sex). HRQoL comparisons with the general (refer-
ence) population are invariably less precise and less pow-
erful as many factors with an influence on HRQoL cannot
be taken into account, such as family history, personal
history (disease), alcohol consumption, tobacco habits,
eating habits, life habits, and social situation. Some stud-
ies have looked at how HRQoL changes over time, but
only in cancer patients with established diagnosis. For
example, Ozyilkan et al. [29] and Funk et al. [30] com-
pared one group before and after treatment with a refer-
ence population. Other studies have estimated reference
population HRQoL scores cross-sectionally [31-33]. None
of them considered either how HRQoL varies over the
period including the diagnosis of cancer, or how it
changes in reference populations. Longitudinal applica-
tion of HRQoL instruments to a general, initially healthy
population would allow for change to be assessed as an
event occurs, rather than afterwards. SU.VI.MAX [34,35]
longitudinally followed up subjects from a general pre-
sumably healthy population, creating an opportunity to
track cancer.
The objective of the present study was to investigate the
impact of new cancer on HRQoL, using a controlled lon-
gitudinal protocol. It is hypothesised that HRQoL was
negatively affected by cancer, particularly when the diag-
nosis is recent.
Methods
SU.VI.MAX study
The data analysed here were drawn from SU.VI.MAX
(SUpplementation en VItamines et Minéraux AntioXi-
dants). SU.VI.MAX was a randomised, double-blind, pla-
cebo-controlled, primary-prevention trial designed to test
the efficacy of daily supplementation with antioxidant
vitamins (vitamin C, 120 mg; vitamin E, 30 mg and beta-
carotene, 6 mg) and minerals (selenium, 100 µg and zinc,
20 µg) at nutrition-level doses in reducing the mortality,
the incidence of cancers (all sites) and ischemic heart dis-
eases in a French general adult population. A total of
13017 eligible subjects (women aged 35 to 60 years and
men aged 45 to 60 years) were enrolled in 1994 and were
followed for up to 8 years with yearly visits (alternately for
laboratory assessment and clinical examination) and
morbidity determination using the Minitel Telematic
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Network, a small terminal used in France as an adjunct to
the telephone.
Data on baseline characteristics of the SU.VI.MAX partici-
pants suggested that the selected subjects were close to the
national population in terms of geographic density, soci-
oeconomic status, and the distribution of various major
risk factors for the diseases under study. The main causes
of exclusion were regular use of supplements or refusal of
placebo [35]. Subjects included were up to 60 years. The
upper cut-off of 60 years was chosen because beyond that
age it may be too late to produce an effect with the
SU.VI.MAX intervention. The age range was chosen to
ensure enough cases of cardiovascular diseases and can-
cers to achieve adequate statistical power in the
SU.VI.MAX study.
HRQoL was a secondary end-point of SU.VI.MAX, with
assessment every two years starting in 1996 (question-
naires were sent out by post and returned at the next yearly
visit). The complete design of the SU.VI.MAX study is as
previously reported [34,35].
HRQoL assessment
Quality of life was assessed using generic questionnaires:
the Medical Outcome Study 36-item short form health
survey (SF-36) [36] and the 12-item General Health Ques-
tionnaire (GHQ-12) [37].
The French-language version of the SF-36 is a validated
instrument [38,39] containing 36 items divided into eight
dimensions of health using multi-item scales: Physical
functioning (10 items), role limitations due to physical
functioning (Role-physical) (4 items), Social functioning
(2 items), Bodily pain (2 items), Mental health (5 items),
role limitations due to emotional functioning (Role-emo-
tional) (3 items), Vitality (4 items) and General Health
perceptions (5 items). The eight scales were scored from 0
to 100 (worst to best possible health status). For each
dimension, the score represented the mean of item values
obtained by the subject when all the items were com-
pleted or when the number of missing values was no more
than half of the total items. Otherwise, the score was
recorded as missing. The frequency of scores for which
fewer than half of a scales items were missing ranged from
0.6% (Role-emotional) to 4.7% (Physical functioning).
The French-language version of the GHQ-12 is widely
administered to screen for common mental disorders [40-
42]. The questionnaire consists of 12 items with four
modalities and measures a global psychological dimen-
sion. Like the SF-36, the dimension score ranged from 0 to
100. The score was computed as the mean of the item val-
ues obtained by the subject when the 12 items were com-
pleted or when 6 or more items were present. Otherwise
the score was declared missing; 3.5% of scores missed
fewer than half the item values.
These questionnaires were chosen by the SU.VI.MAX
investigators for their ability to detect change in HRQoL
when a disease occurs, particularly cancer (sensitivity to
change), and because they have sufficient validity [43].
Internal consistency ranged from 0.80 to 0.92 according
to the SF-36 dimensions [44]. In our sample, we found
Cronbach's α coefficients ranging between 0.77 and 0.86.
A comparison between the Mental health dimension of
SF-36 and the GHQ-12 global score showed the two
instruments to have similar psychometric performance
(Cronbach's α coefficients were 0.91 and 0. 84 and relia-
bility coefficients were 0.92 and 0.88 for GHQ-12 and SF-
36 Mental health dimension respectively), although
GHQ-12 is used to detect psychiatric cases, whereas SF-36
estimates mental health in general populations [45].
According to Goldberg et al, psychometric properties of
the reduced GHQ versions were comparable to those of
the original version. Cronbach's α coefficient was up to
0.8 and the test-retest coefficient was 0.73 for the GHQ-12
[37]. In our sample, Cronbach's α coefficient was 0.87.
SF-36 and GHQ-12 findings at the two first time points,
1996 (T1) and 1998 (T2), were used for the present
purposes.
Morbidity assessment
Morbidity was initially addressed in the SU.VI.MAX inclu-
sion questionnaire. Characteristics of interest included:
the presence of cancer, body mass index, alcohol con-
sumption, tobacco habits, physical tiredness, cardiovascu-
lar disease, diabetes, digestive disorders (stomach or
duodenal ulcer, viral hepatitis, intestinal amebiasis, intes-
tinal polyp, hiatal hernia, diaphragmatic hernia or gall-
stones), miscellaneous comorbid conditions (including
asthma, rheumatism, rheumatoid arthritis or renal colic),
and number of symptoms (signs of blackout, chest pain,
shortness of breath, palpitations, limp, metrorrhagia, leu-
korrhagia, hemoptysis, hoarseness, dysphagia, gastric
pain, intestinal transit problems, rectorrhagia, hematuria,
dysuria, pollakiuria, cough-triggered urinary inconti-
nence, cephalgia, rheumatalgia).
During the follow-up period, monitoring of the same
comorbidities was by yearly visits (alternately for assess-
ment of laboratory parameters and clinical examination).
Details of any abnormality detected were sent to the sub-
ject concerned for forwarding to his or her physician.
Thereafter, contact was maintained with the participant
and the physician in order to monitor medical supervi-
sion and verify the conclusions of follow-up visits. In
addition, the Minitel allowed participants to provide and
receive information via the main SU.VI.MAX computer
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server. They were able to complete computerised ques-
tionnaires off-line and transmit data during brief tele-
phone connections. Each month, participants had an
opportunity to report any health events, medical consul-
tations or hospitalisations that had occurred since the pre-
vious assessment. When they occurred, an in-depth
investigation was undertaken involving the subject or his
or her family (in case of death) and any relevant medical
personnel (general practitioner or hospital staff, for exam-
ple). If the Minitel connection was broken for a long
period, or if a participant failed to appear at a SU.VI.MAX
follow-up visit, an investigation was launched to deter-
mine why and to monitor the subject's subsequent partic-
ipation. If the family or the SU.VI.MAX investigators
reported the death of a patient, the official death certifi-
cate was obtained and the cause of death determined.
When a suspected event occurred, all relevant records,
including the results of diagnostic tests and procedures
(imaging, endoscopy, cytology, biopsy, surgery, etc.) were
collected from the subject or the relevant hospital, labora-
tory, or institution, and scrutinised at the SU.VI.MAX co-
ordinating centre. Cancer-related information – i.e. type
of cancer (cancer histology), stage, date of diagnosis (as
confirmed on the pathology report), treatment at the time
of diagnosis, and date of treatment were ascertained by
research staff trained to conduct medical reviews and con-
firmed by mandatory provision of histological evidence.
Subjects
Because 3 recruitment centres were – for logistic reasons –
unable to participate in the HRQoL study, only 9223 sub-
jects are considered here; 7468 (81%) filled in T1 HRQoL
questionnaire. Those in whom cancers developed
between T1 and T2 were defined as cancer cases. If T2 data
were missing, the period T1 + 2 years was considered.
Those who had a cancer occurrence before T1 were
excluded. The constitution of the groups was as illustrated
in Figure 1.
Subjects' inclusion processFigure 1
Subjects' inclusion process.
24 CANCER SUBJECTS 
WITHOUT T2 HRQOL
MEASURES
84 CANCER SUBJECTS 
WITH 2 HRQOL
MEASURES
420 CANCER-FREE 
CONTROLS WITH 2
HRQOL MEASURES
 RANDOM   SELECTION
108 CANCER 
SUBJECTS
88 SUBJECTS WITH 
CANCER DIAGNOSIS 
BEFORE T1 HRQOL
MEASURE
1449 SUBJECTS 
WITHOUT T2
HRQOL MEASURE
5823 SUBJECTS
WITH THE 2 HRQOL
MEASURES
7468 SUBJECTS WITH 
T1 HRQOL MEASURE
7380 SUBJECTS
7272 SUBJECTS 
WITHOUT CANCER
EXCLUSION
EXCLUSION
EXCLUSION
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The controlled longitudinal study of the impact of cancer
occurrence involved:
• 84 of 108 cancer cases for whom there were both T1 and
T2 data; and
• 420 age- and sex-matched controls randomly selected
from among a subsample of the 7272 cancer-free subjects:
5823 subjects (80.1%) filled in the T2 HRQoL
questionnaire.
With 84 cancer cases, 420 controls were required to detect
a difference of 5 points on the SF-36 scale between the two
groups using a type I error of 5%, an estimated mean
standard deviation of 20, and a power of 80%.
All subjects were selected regardless of how they had been
randomised in SU.VI.MAX, the double-blind code of
which was not broken.
Statistical analysis of data
Descriptive analysis
All descriptive statistics are presented as means and stand-
ard deviations for quantitative variables, and as absolute
and relative frequencies for categorical variables. HRQoL
scores are presented as means with their 95% confidence
intervals.
Controlled longitudinal study of the impact of cancer 
occurrence
Cancer and cancer-free groups were compared for initial
characteristics. Tests based on chi-square and on the t-test
were used for categorical and quantitative variables,
respectively. Factors that differed between the two groups
were selected as adjustment variables in the multivariate
analysis.
First, the HRQoL scores for the two groups were compared
at T1 (i.e. before cancer occurrence), to confirm that they
were similar. Second, the impact on HRQoL over time of
cancer occurrence was assessed using a linear mixed
model for repeated measures; within variables were the
two measures of HRQoL, and between variables were
group and adjustment variables.
Two levels of type I error were used:
- 10% to determine a statistically significant difference
between those variables to be considered as adjustment
variables in the multivariate analysis.
- 5% to determine statistical significance in the final mul-
tivariate analysis.
Statistical analysis was performed using SAS ® system [46].
Results
Cancer subjects characteristics
In the cancer group, ages ranged between 36 and 61 years,
with a mean of 51 years; 61 subjects (56.5%) were female.
Eighty-four (79%) of 108 subjects had both T1 and T2
HRQoL data. The disease characteristics of this subgroup
are presented in Table 1.
Most cancers were of the breast (21.4%), cutaneous
(30.9%), colo-rectal (13.1%), or prostatic (14.3%). Mean
time between date of cancer diagnosis and T2 was 15.2
months (range, 2 days to 2 years). The majority of cases
were at stage 0, I or II (95.1%), and treatment was essen-
tially surgical (88.1%). Mean time between surgery and T2
was 15.6 months (range, 13 days to 2 years). With regard
to the 24 subjects for whom T2 data were missing, no dif-
ference in initial characteristics were observed compared
with the remainder, other than that they had more physi-
cal tiredness. Types of cancer were: breast (n = 6), cutane-
ous (n = 3), lung (n = 3), colo-rectal (n = 2), prostate (n =
1), hematologic (n = 4), bladder (n = 2), and other (n =
3). 58.3% had surgery, 33.4% had radiotherapy and
29.2% had chemotherapy. 70.6% were at stage 0, I or II.
One reason for missing T2 data was death (11 subjects). 5
died subjects were at stage III or IV. HRQoL scores at T1
were non-significantly lower in the group without T2
data. General health and Mental health dimensions were
most affected, with differences in scores of 9.6 (p = 0.01)
and 8 (p = 0.05), respectively.
Controlled longitudinal study of the impact of cancer 
occurrence
Characteristics of the cancer and cancer-free groups are
illustrated in Table 2. There was no difference between the
2 groups except that the cancer group was more likely to
be educated to high school diploma level (p = 0.09), and
felt more physical tiredness (p = 0.07).
After adjustment taking into account theses differences,
HRQoL scores at T1 (i.e. before cancer occurrence) were
similar in the two groups (Table 3). At T1, the cancer
group had non-significantly higher scores in all dimen-
sions other than Role-physical and Role-emotional,
which were non-significantly lower. Between T1 and T2,
all HRQoL scores decreased in the cancer group, whereas
those of the cancer-free group were unchanged. The
impact of cancer occurrence was most pronounced in the
Physical functioning, Role-physical and General health
dimensions. The difference in change (defined as the dif-
ference between the cancer and cancer-free groups in how
much HRQoL changed) ranged from -6.6 (Physical func-
tioning) to -15.2 (Role-physical). In the Bodily pain and
Vitality dimensions, the difference in change was -6.3 and
-4.4, respectively. The Role-emotional, Mental health and
Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/4
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Social functioning dimensions and the GHQ-12 score
were not significantly affected by a cancer occurrence.
Comparisons with HRQoL scores in the general French 
population
When looking for HRQoL scores in a representative sam-
ple of the general French population (45–54 years) [44],
the scores in the cancer-free group were lower, with abso-
lute differences of 5 points maximum in all dimensions of
the SF-36 except Bodily pain and Mental health (differ-
ence about 7 points).
HRQoL scores in the cancer-free group were lower com-
pared to scores observed in a sample without chronic dis-
ease (except Role-emotional and Social functioning), and
better compared to scores observed in a sample with
chronic disease. In most of the dimensions, absolute dif-
ferences were of 5 points maximum [43].
Discussion
The results of the present study show that cancer occur-
rence had a negative impact on HRQoL. The effect of can-
cer was strong in all dimensions of the SF-36 (other than
Mental health, Role-emotional and Social functioning),
and particularly so in Physical functioning, Role-physical,
Bodily pain and General health, for which there was an at
least 6.3 point difference in change in HRQoL over time.
The GHQ-12 score was not at all affected by cancer
occurrence.
The choice of outcome measure may have important
effects on the results of studies such as this. HRQoL instru-
ments are used on the assumption that they are valid, reli-
able and sensitive [43]. The SF-36 has been shown to be
valid and reproducible [38,39], and the GHQ-12 has
comparable psychometric performance to that of the
mental dimension of SF-36, although their objectives are
complementary [45]. GHQ-12 has been used as a psychi-
atric screening instrument and to describe the mental
health of a defined population. The SF-36 questionnaire
has proven to be useful in monitoring general and specific
populations, comparing the burdens of different diseases,
differentiating the health benefits of different treatments,
and in screening individual patients.
A generic tool was used in the present study both because
a general population was involved and in order to allow
for a controlled comparison with it. Generic measures
Table 1: Cancer group characteristics (n = 84)
n proportion mean sd a
Site
Breast 18 21.4
Cutaneous 26 30.9
Colo-rectal 11 13.1
Gynaecological 2 2.4
Hematologic 3 3.6
Prostate 12 14.3
Lung 1 1.2
Thyroid 8 9.5
Bladder 2 2.4
Other 1 1.2
Stage at diagnosis of solid cancer
0 (in situ) 6 7.4
I 43 55.6
II 28 32.1
III 3 3.7
Unknown 1 1.2
Time between diagnosis and T2 QoL assessment (months) 15.2 7.9
Treatment before T2 QoL assessment
Surgery 74 88.1
Time between treatment and T2 (months) 15.6 7.7
Radiotherapy 18 21.4
Time between treatment and T2 (months) 13.9 8.4
Chemotherapy 9 10.7
Time between treatment and T2 (months) 10.6 6.6
No treatment 7 8.3
a standard deviation
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cover a broad range of HRQoL dimensions in a single
instrument and are applicable in a wide variety of popula-
tions, but they are less responsive than specific tools that
focus on a particular disease or symptom.
As in most longitudinal investigations, part of the present
initial sample was lost to follow-up. It is possible that the
factors that led people to refuse to participate or to give up
the study between T1 and T2 were related to their state of
health.
SUVIMAX inclusion criteria (age up to 60 years) mean
that the cancer cases may only represent the population of
cancer occurring before 64 years which are a few part of
overall cancers. However, it is likely that the impact of
cancer on HRQoL doesn't vary much with age.
HRQoL scores in the control group are similar to norma-
tive scores described elsewhere [43,44], supporting the
validity of our control group. HRQoL among cancer-free
controls changed little over the 2 years of follow-up except
for a minor improvement (+ 2 points maximum in 2
years) in most dimensions.
Although the cancer group was small and diverse, there
were sufficient data concerning characteristics such as
stage of disease and treatment to show that the cancer
group was relatively homogeneous in terms of stage (no
stage IV and 3 stage III cancers) and treatment (essentially
surgical). The mean time between date of surgery and the
second HRQoL measurement was 15 months, perhaps
leading to a reduce impact of treatment on T2 HRQoL
assessment. The sample size did not permit the analysis to
be limited to subjects with the same type of cancer, but
when stage III was excluded, the results were similar to
those presented here, confirming their validity. Moreover,
the same results were found when the analyses were
repeated excluding cutaneous cancers (which are reputed
to be less aggressive), but retaining melanoma. No analy-
sis by cancer site was possible because of lack of power.
Lack of power due to the small sample size may have pre-
vented some of the present results from reaching statisti-
cal significance. However, sufficient power was available
to detect differences of 5 points from the respective con-
trol groups (the matching strategy increased the power).
The literature on the SF-36 health survey shows that very
small differences on the SF-36 can be interpreted as clini-
cally important. Anyway a difference of 5 points of mean
HRQoL scores on a 0–100 scale is considered to be clini-
cally and socially relevant [47].
Table 2: Comparison of initial characteristics in the cancer (n = 84) and cancer-free (n = 420) groups
Cancer Cancer-free p value b
n proportion mean sd a n proportion mean sd a
Age (years) 50.9 5.6 50.9 5.5 1.00
Female 48 57.1 240 57.1 1.00
Alone 13 15.9 59 14.4 0.73
Higher diploma 0.09
Without diploma 3 3.6 19 4.5
Less than High school diploma 21 25.0 154 36.7
High school diploma and higher 60 71.4 247 58.8
Body Mass Index (kg/m2) 23.8 3.6 24.1 3.5 0.43
Alcohol consumption (g/day) 22.5 25.1 20.5 22.9 0.48
Tobacco habits 0.46
Non-smoker 43 51.2 214 51.5
Former smoker 34 40.5 149 35.8
Current smoker 7 8.3 53 12.7
Tobacco consumption (cigarette-year) 7.8 12.5 6.9 11.8 0.54
Physical tiredness 19 22.9 61 14.7 0.07
Morbid conditions
Cardiovascular disease 1 1.2 8 1.9 1.00
Diabetes 2 2.4 4 1.0 0.26
Digestive disorder c 22 26.8 100 24.9 0.78
Miscellaneous comorbid conditions d 17 20.5 95 24.1 0.57
Number of symptoms (at enrolment) e 3.0 2.2 2.9 2.5 0.74
a standard deviation b from t-test for quantitative variables and from chi square for categorical variables c gastric or duodenal ulcer, viral hepatitis, 
intestinal amebiosis, intestinal polyp, hiatal hernia or diaphragmatic hernia or gallstones. d asthma, rheumatism, rheumatoid arthritis or renal colic. e 
sum of different signs (see text)
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All subjects were selected regardless of how they had been
randomised in SU.VI.MAX, the double-blind code of
which was not broken. SU.VI.MAX was designed to test
the efficacy of daily supplementation over a period of 8
years. Our studies used data from 1996 and 1998 (i.e. 4
years at most after the start of daily supplementation). We
can reasonably suppose that any protective effect would
not yet have been sufficient in this laps of time to influ-
ence estimates of the impact of cancer on HRQoL.
The study design adopted here offers the opportunity to
track cancer occurrence. Controlled longitudinal analysis
enables changes in HRQoL to be monitored over the
period of diagnosis. In contrast, most other investigations
look at the impact on HRQoL of existing cancer. The
present protocol provides an opportunity to compare
HRQoL in cancer subjects with that in controls using lon-
gitudinal strategies. Compared with the use of normalised
data, selection of controls from the same population as
the study group leads to a reduction in inter-individual
variability. Enrolling controls in the population from
which the cancer cases occurred also allowed HRQoL
scores to be adjusted for age, sex, and comorbid condi-
tions. In addition, two measures were performed for both
the cancer and the control groups, thus more reducing
inter-individual variability. Comparison between cancer
patients and controls was also more precise and more
powerful.
The acute situation facing patients with a new diagnosis of
cancer was expected to have a negative effect on HRQoL.
However, although all dimensions were indeed negatively
affected by the event, recently diagnosed subjects still had
a relatively high HRQoL. This may reflect the ability peo-
ple have to cope with new situations. The dimensions
most impaired by the cancer occurrence were Physical
functioning, Role-physical and Bodily pain, all of which
have a physical aspect. This is not surprising given that the
cancer would have been recently diagnosed and treated
essentially by surgery. Some indices, particularly the men-
tal and emotional dimensions, were less affected by can-
cer occurrence. Courtens et al. [13] found that although
functioning and physical and psychological well-being
were negatively affected by cancer, newly diagnosed
patients were satisfied with life in general and had high
HRQoL. Cancer patients receive more attention and sup-
port from family and friends than do healthy subjects.
They may also learn to value life in other, often new, ways.
These results underline the importance of the psychologi-
cal capacity human beings have to adapt and to cope with
stressful life events, such as getting cancer. It has been sug-
gested that newly diagnosed (not terminally ill cancer
patients) still have a chance of cure that may strengthen
the psychological domains of HRQoL.
Parker et al found in their sample of cancer patients that
SF-12 physical score was lower that of the general popula-
tion, and SF-12 mental score was comparable to that of
Table 3: Comparison of HRQoL scores in the cancer (n = 84) and cancer-free (n = 420) groups.
T1 T2
Cancer Cancer-free p value d Cancer Cancer-free difference 
in change e
p value f
mean a LL b UL c mean a LL b UL c mean a LL b UL c mean a LL b UL c
SF-36
Physical 
functioning
90.2 86.5 93.9 87.9 85.4 90.4 0.18 84.5 80.9 88.2 88.8 86.3 91.3 -6.6 <.0001
Role-
physical
80.7 73.7 87.7 82.7 78.3 87.1 0.56 65.3 58.3 72.3 82.5 78.1 86.9 -15.2 0.0004
Bodily pain 69.8 64.6 75.1 69.5 66.1 72.9 0.90 62.2 57.0 67.5 68.2 64.8 71.6 -6.3 0.01
Mental 
health
67.5 63.3 71.6 65.6 62.8 68.4 0.34 65.2 61.0 69.3 66.8 64.0 69.5 -1.1 0.07
Role-
emotional
78.5 70.7 86.2 79.9 75.1 84.8 0.70 70.6 62.9 78.3 79.5 74.7 84.4 -7.5 0.11
Social 
functioning
81.4 76.4 86.4 80.6 77.4 83.8 0.76 77.3 72.3 82.3 81.3 78.1 84.5 -4.8 0.09
Vitality 60.1 55.9 64.2 59.1 56.3 61.8 0.61 57.1 52.9 61.2 60.2 57.4 62.9 -4.4 0.03
General 
health
71.7 67.4 76.0 68.7 65.8 71.6 0.14 62.6 58.3 66.8 70.7 67.9 73.6 -11.1 <.0001
GHQ-12 69.7 66.7 72.8 68.9 66.9 70.9 0.58 68.8 64.9 71.1 69.5 67.5 71.5 -2.3 0.17
HRQoL = health-related quality of life Scores range from 0 to 100, the higher the score, the better the HRQoL a adjusted mean b lower limit of the 
95% confidence interval c upper limit of the 95% confidence interval d test of equality of T1 HRQoL score from a linear mixed model adjusted for 
higher diploma and physical tiredness e mean score evolution (cancer) – mean score evolution (cancer-free) f test of the interaction between time 
and group from a linear mixed model adjusted for higher diploma and physical tiredness
Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/4
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the general population, despite some cancer patients
reporting significant depressive symptoms [48]. Other
studies focused on the impact of cancer on mental health,
showing that the diagnosis and treatment of cancer may
be associated with anxiety and depression [49-52]. A
recent review of the benefits of psychosocial oncology care
stated that patients at high risk for distress are those with
later stage disease, poorer prognosis, greater disease bur-
den and perhaps younger age [53]. These subgroups are
not represented in our sample. This may be why cancer
occurrence seemed not to affect mental domains and one
may hypothesise that the mental burden of cancer occurs
along the course of the disease, with harmful medical
intervention and degradation of health status [16,54-56].
The varied schedule of HRQoL measurement after cancer
occurrence raises questions about the causes of the nega-
tive observed impact, including: the diagnosis itself, treat-
ment, side effects, natural course of the cancer. HRQoL
evolution as measured by the EORTC-QLQC30 before
and after treatment has been assessed in a sample of
female cancer patients. Before treatment, global HRQoL
and emotional functioning were more affected than
physical and social functioning. At the first assessment
after treatment, physical, role and social functioning
decreased significantly. Emotional functioning and global
HRQoL improved significantly between pre-treatment
and post treatment [57]. Between 3 months and 15
months after surgery for breast cancer, HRQoL of women
aged 65 years or older showed significant declines for
physical (difference about 10 points) and mental (differ-
ence about 3 points) functioning's [58]. Assessments of
HRQoL 3 months and 1 year after surgery for breast cancer
showed that all dimensions improved over time, but only
social and emotional functioning showed a moderate
effect size (i.e. between 0.20 and 0.50) [55]. HRQoL as
measured by the SF-36 in long-term, disease-free survivors
of breast cancer decreased (weakly clinically but statisti-
cally significantly) over time in Physical functioning,
Role-physical, Bodily pain and General health, whereas
Mental health improved over time [59].
Conclusion
The negative impact of cancer on the lives of patients was
assessed in terms of HRQoL. The aspects most likely to be
affected were those with a physical component, and gen-
eral health perceptions. These results can thus help quan-
tify the impact of a new cancer on ongoing HRQoL, and
potentially maximise the benefit of early intervention by
enabling the most affected HRQoL domains to be tar-
geted. It would be of interest for future studies to investi-
gate the relationship between time since diagnosis and
HRQoL. Further follow-up of SU.VI.MAX to obtain more
HRQoL data should help elucidate the relationship. Each
cancer subject can potentially have four HRQoL measures:
one before the cancer emerges and the remainder
afterwards.
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